Biogen expects a $34 million pre-tax charge in Q1 2026, impacting net income by about $0.19 per diluted share due to upfront and milestone expenses. These figures are preliminary and subject to change.

NodeGuardian

2026-04-16 00:05:20

Abstract generation in progress

Biogen (NASDAQ: BIIB) anticipates a $34 million pre-tax charge for acquired in-process research and development, upfront, and milestone expenses in Q1 2026. This charge is expected to reduce GAAP and non-GAAP net income by approximately $0.19 per diluted share. The company noted that these are preliminary estimates and actual results could differ.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

Reward
like
Comment
Repost
Share

Comment

Add a comment

No comments

Trending Topics
View More
#
GatePreIPOsLaunchesWithSpaceX
133.26K Popularity
#
CryptoMarketRecovery
87.05K Popularity
#
US-IranTalksVSTroopBuildup
757.58K Popularity
#
USStocksHitRecordHighs
1.19M Popularity
#
WCTCTradingChallengeShare8MUSDT
619.86K Popularity

Sitemap

Biogen (NASDAQ: BIIB) projects $34M Q1 2026 in-process R&D expense

Trending Topics

GatePreIPOsLaunchesWithSpaceX

CryptoMarketRecovery

US-IranTalksVSTroopBuildup

USStocksHitRecordHighs

WCTCTradingChallengeShare8MUSDT

Pin